Photo by nci from unsplash
Present data revealed higher event rates in patients who underwent everolimus-eluting bioresorbable scaffold (BRS) implantation compared with patients treated with metallic drug-eluting stents (DES). Of these studies, only 1 randomized… Click to show full abstract
Present data revealed higher event rates in patients who underwent everolimus-eluting bioresorbable scaffold (BRS) implantation compared with patients treated with metallic drug-eluting stents (DES). Of these studies, only 1 randomized trial is available, which addresses BRS use in patients with
Keywords:
trial;
drug eluting;
eluting stents;
everolimus eluting;
eluting bioresorbable
Journal Title: Journal of the American College of Cardiology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!